Methyldopa tablet labels and packages: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==Labels | ==Labels and Packages== | ||
Principal Display Panel | Principal Display Panel | ||
Revision as of 20:08, 12 March 2014
Methyldopa |
---|
Methyldopa tablet® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings |
Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
Methyldopa injection® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings |
Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
Clinical Trials on Methyldopa |
ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Labels and Packages
Principal Display Panel
Methyldopa Tablets, USP
250 mg
10 Tablets
References
- ↑ "METHYLDOPA TABLET [CARDINAL HEALTH]". Retrieved 10 March 2014.